Davenport Downgrades Orexigen Therapeutics (OREX) to Neutral
Tweet Send to a FriendGet Alerts OREX Hot Sheet
Price: $6.45 -0.46%
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade OREX Now!
Davenport downgrades Orexigen Therapeutics (Nasdaq: OREX) from Buy to Neutral.
To see all the upgrades/downgrades on shares of OREX, visit our Analyst Ratings page.
Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity.
To see all the upgrades/downgrades on shares of OREX, visit our Analyst Ratings page.
Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity.
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- BGC Partners Downgrades DuPont (DD) to Sell
- Janney Montgomery Scott Downgrades Cubist Pharmaceuticals (CBST) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Davenport
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
